LON:ETX e-therapeutics (ETX) Share Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free ETX Stock Alerts GBX 9 -0.65 (-6.74%) (As of 05/8/2024) Add Compare Share Share Today's Range 9▼ 10.7550-Day Range 8.66▼ 12.9052-Week Range 8▼ 24Volume2.52 million shsAverage Volume758,869 shsMarket Capitalization£52.59 millionP/E RatioN/ADividend Yield3.35%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get e-therapeutics alerts: Email Address Ad InvestorPlaceHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market.Click for his six specific AI stock in the crosshairs About e-therapeutics Stock (LON:ETX)e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.Read More ETX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETX Stock News HeadlinesMay 17 at 5:22 AM | americanbankingnews.come-therapeutics (LON:ETX) Stock Crosses Below Two Hundred Day Moving Average of $11.67May 14, 2024 | markets.businessinsider.comERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024May 9, 2024 | markets.businessinsider.come-therapeutics plc shares now trading on JP JenkinsApril 20, 2024 | lse.co.ukE-therapeutics Share ChatApril 11, 2024 | msn.comEliem Therapeutics to buy Tenet, announces $120 million private placementApril 10, 2024 | seekingalpha.comAquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024April 10, 2024 | lse.co.uke-Therapeutics says company faces lack of interest as UK listingApril 10, 2024 | marketwatch.come-Therapeutics Shares Fall on London Delisting Plan; Mulls Move to New YorkApril 10, 2024 | msn.com‘Lack of appetite’ in London drives another high-tech firm to NasdaqApril 10, 2024 | msn.comDrug discovery firm e-therapeutics to quit London Stock Exchange following £29m fundraiseMarch 16, 2024 | msn.comAquestive maps out FDA approval for sublingual anaphylaxis drugJanuary 3, 2024 | finance.yahoo.comWe're Hopeful That e-therapeutics (LON:ETX) Will Use Its Cash WiselyDecember 27, 2023 | msn.comMedical innovator e-therapeutics to stop trading on US-based marketNovember 13, 2023 | markets.businessinsider.comEdison issues update on e-therapeutics (ETX): More to come in RNAi therapy discoveryOctober 30, 2023 | businesswire.comEvecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot EhrichOctober 26, 2023 | proactiveinvestors.comE-therapeutics bolsters generative AI integration and strategic...September 28, 2023 | benzinga.comU.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaSeptember 28, 2023 | marketwatch.comQuince Therapeutics to Advance Study of EryDex as FDA Lifts Application HoldSeptember 20, 2023 | proactiveinvestors.come-therapeutics appoints new CFOJuly 13, 2023 | uk.finance.yahoo.comETX.L - e-Therapeutics plcJune 8, 2023 | wsj.comElicio Therapeutics Inc.May 23, 2023 | businesswire.comAgeX Therapeutics Announces Appeal of NYSE American DeterminationMay 10, 2023 | businesswire.comRapid Dose Therapeutics Launches QuickStrip™ Dental Products in the Canadian MarketMay 10, 2023 | marketwatch.comDelix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001May 6, 2023 | marketwatch.comAcute Renal Failure Therapeutics Market Located Worldwide Trends and Application – Baxter,Teva Pharmaceutical,PfizerSee More Headlines Receive ETX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/17/2020Today5/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ETX CUSIPN/A CIKN/A Webwww.etherapeutics.co.uk Phone+44-1993-880000FaxN/AEmployees34Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-10,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.75% Return on Assets-29.10% Debt Debt-to-Equity Ratio0.33 Current Ratio22.20 Quick Ratio20.13 Sales & Book Value Annual Sales£295,000.00 Price / Sales178.27 Cash FlowGBX 1.77 per share Price / Cash Flow5.07 Book ValueGBX 5 per share Price / Book1.80Miscellaneous Outstanding Shares584,330,000Free FloatN/AMarket Cap£52.59 million OptionableNot Optionable Beta0.46 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Ahmad Ali Mortazavi (Age 53)CEO & Director Comp: $270kMr. Timothy BrethertonCFO, Director of Finance & Operations and Company SecretaryDr. Laura Roca-Alonso Ph.D.Chief Operating & Business OfficerMr. Alan Whitmore B.Sc.Ph.D., Chief Scientific OfficerMr. Ankit SharmaHead of Software EngineeringMr. Graham CraggsHead of Therapeutic DiscoveryMore ExecutivesKey CompetitorsRedx PharmaLON:REDXSareumLON:SARTissue Regenix GroupLON:TRXArecor TherapeuticsLON:ARECOpen OrphanLON:ORPHView All CompetitorsInsidersTrevor Mervyn JonesBought 91,325 shares on 1/9/2024Total: £730,600.00 ($8.00/share)Trevor Mervyn JonesBought 34,830 shares on 7/6/2023Total: £766,260.00 ($22.00/share)View All Insider Transactions ETX Stock Analysis - Frequently Asked Questions How have ETX shares performed in 2024? e-therapeutics' stock was trading at GBX 8.24 on January 1st, 2024. Since then, ETX shares have increased by 9.2% and is now trading at GBX 9. View the best growth stocks for 2024 here. How were e-therapeutics' earnings last quarter? e-therapeutics plc (LON:ETX) released its quarterly earnings results on Tuesday, March, 17th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.03. What other stocks do shareholders of e-therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other e-therapeutics investors own include Radware (RDWR), Sound Energy (SOU), 4D pharma (DDDD), Chicken Soup for the Soul Entertainment (CSSE), Crescent Point Energy (CPG), Collagen Solutions plc (COS.L) (COS), BP (BP), Bushveld Minerals (BMN) and Alstom (ALSMY). How do I buy shares of e-therapeutics? Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:ETX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding e-therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.